1. 19 AN OBJECTIVE GENETIC ONTOGENY CLASSIFICATION IDENTIFIES TRUE BIOLOGICAL SECONDARY AML AMONG DE NOVO AML PATIENTS ≥60 YEARS OLD. (April 2015) Authors: Lindsley, R.C.; Mar, B.G.; Mazzola, E.; Grauman, P.G.; Lindeman, N.; Steensma, D.P.; DeAngelo, D.J.; Wadleigh, M.; Neuberg, D.; Stone, R.M.; Ebert, B.L. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early Mortality Due to Cardiovascular Disease for Patients with Myelodysplastic Syndromes (MDS) Living in Areas with Lower Cardiovascular Performance Outcomes. (April 2017) Authors: Brunner, A.; Blonquist, T.; Neuberg, D.; Fathi, A. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1282: DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS. (23rd June 2022) Authors: Nadeu, F.; Shuai, S.; Clot, G.; Hilton, L. K.; Diaz-Navarro, A.; Martín, S.; Royo, R.; Baumann, T.; Kulis, M.; López-Oreja, I.; Cossio, M.; Lu, J.; Ljungström, V.; Young, E.; Plevova, K.; Knisbacher, B. A.; Lin, Z.; Hahn, C. K.; Bousquets, P.; Alcoceba, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY. (23rd June 2022) Authors: Brunner, A.; Liu, Y.; Mendez, L.; Garcia, J.; Amrein, P.; Neuberg, D.; Dean, E.; Smith, S.; Stone, R.; Fathi, A.; Walter, M.; Graubert, T.; Jacoby, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 653 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-97 Overall survival with warfarin versus low-molecular-weight heparin in cancer-associated thrombosis. Issue 200 (April 2021) Authors: Patell, R.; Chiasakul, T.; Redd, R.; Khan, A.M.; McCarthy, E.P.; Neuberg, D.; Zwicker, J.I. Journal: Thrombosis research Issue: Issue 200(2021)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗